Member Info for ontarget

Kight added another 1% https://www.lse.co.uk/rns/EVG/holdings-in-company-eftx5foewuvh6vt.html
Stealthy!

Could be https://www.wg-plc.com/product/boss-iii-body-orifice-security-scanner

Yes, just needs the one RNS we are all waiting for 'Ratification and operations commenced'. Can't be long now surely?..
Assuming it's not fallen through of course!!!!

Yes good idea Hemotruth. Let's all listen to a 2-post poster who has just turned up instead (what was your previous alias btw?).
You're correct I did hold a large holding between 2018 and 2020 and was very lucky to sell out with significant profit on that COVID RNS spike. But still follow the company and stock as it's an interesting story and obviously heavily researched at the time - is that ok with you?

Looks like the initial 10,000 square feet is going to be costing them around $1M/year.
Info from last year:
https://www.crainsnewyork.com/commercial-real-estate/lab-space-experiencing-breakthrough-struggling-market
Let's hope Vlad does find some 'non dilutive' funding before renting even more buildings!!

Sounds very expensive for a company with no income.

It’s to allow the company to pay out dividends in the coming highly profitable years.

Let's not turn this thread into a bullying one where only one opinion is allowed, there's enough of them around on this website.
Clearly the shareprice is currently reflecting a mixture of views in the market.

He ended up licencing his own drug from a major instead of licencing it TO them, which is what junior pharma's are supposed to do and all strive for. If this is not a blunder, what is?

18 months ago (and longer) the big hope was Vlad would licence CDX to Lilly, get cash upfront and royalties etc. and Lilly would fund the trials. This is the goal of most junior pharma's - to licence their potential drug to a major.
What was announced today was the opposite of this though (and yes it was well flagged earlier in the year when Lilly declined to licence CDX). Not sure why people expected a significant rise on this?
To me this is now Vlad's second serious blunder alongside the CLN debacle resulting in more than a doubling of shares in issue.

This does usually point to a placing with those select few in-the-know dumping while everyone else is scratching their heads (is it a coincidence that this BB went deathly quiet recently?).
However at the same time the company have repeatedly said publicly they don't intend to raise at this stage - and also it would surely be a bonkers thing to do, both from a credibility and shareprice growth point of view.
Bit of a mystery - just hope poor old PI is not in for another shafting here.

Closed in the blue. Could be back to 6p this month.

But it's HEMO who are licencing from Eli Lilly, not the other way around unfortunately.
Yes Globalco are Eli Lilly - HEMO announced it in an RNS.

Did you see how quickly it moved earlier when we had 4 x 500k buys in a row.

Just not enough volume on the buy side.
So the real question is why is there so little buying interest.

They have previously said the drill would take 28 days. Doubt they would get this wrong?

Close to $85/barrel now and both this stock and BB are like a ghost town with 3-4 weeks to go until spud.
All very odd.

"red list for entering England"

That's about $980M then.

You can't use prices to 2 DP as precise support/resistance levels. There is a resistance level/zone around 3.5-3.7p we have yet to break.